The 3 analysts offering 12-month price forecasts for Immunovant Inc have a median target of 24.00, with a high estimate of 30.00 and a low estimate of 21.00. The median estimate represents a +49.35% increase from the last price of 16.07.
The current consensus among 3 polled investment analysts is to Buy stock in Immunovant Inc. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share --
Reporting Date TBD
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.